iconstar paper   HIV Articles  
Back grey arrow rt.gif
HIV Broadly Neutralizing Antibodies Research; treatment/cure/interruptions
  NIH Press Release: Three-in-one antibody protects monkeys from HIV-like virus
NIH and Sanofi scientists prepare to test antibody in people.
September 20, 2017
Three-in-One Antibody Protects Monkeys from SHIV - HIV-Like Virus - (09/20/17)
ART Interruptions are the soup de jour in cure research - either until the participant reaches 50 copies, or 1000 copies of viral load or in these 2 cases presented at IAS - 1 - semen viral load also was measured and occurred and - 2 - participants viral load rebounded up to 10,000 and above on left off therapy for a long time. We do NOT know the long term affects of repopulating reservoirs after interruptions in people who had undetectable viral load. NOR does informed consent adequately address these issues. Unethical. Jules
IAS: 2 ART Interruption Cure Studies at IAS 2017 - (09/20/17)
ART Interruption Associated with HIV in the Brain: "Reseeding CNS during ART Interruption Leading to Intrathecal Immune Activation" - "HIV-1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment" - (09/18/17)
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption - (06/27/16)
Broadly Neutralizing Antibody Immunotherapy for HIV-1
www.natap.org/2017/HIV/PIIS1931312817302937(1).pdf by Y Nishimura - 2017

3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption

This study evaluates the effects of two infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART and its safety during a brief analytical interruption of antiretroviral therapy.
3BNC117-LS First-in-Human Phase 1 Study
This study is a phase 1, open label, dose-escalation study of the mAb 3BNC117-LS administered intravenously in HIV (human immunodeficiency virus)-uninfected individuals and HIV-infected individuals. The objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of a single infusion of 3BNC117-LS in HIV-uninfected and HIV-infected individuals.
3BNC117 and 10-1074 in HIV-infected Individuals
3BNC117 and 10-1074 in HIV Uninfected Adults
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 https://clinicaltrials.gov/ct2/show/NCT02511990?term=10-1074&rank=2
Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART (eCLEAR)

Analytic treatment interruption (ATI) study [TimeFrame:64 weeks]
Time to plasma HIV RNA >1000 c/mL on two consecutive measurements
3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption https://clinicaltrials.gov/ct2/show/NCT02446847?term=(HIV)+broadly+neutralizing+antibodies&draw=1&rank=6
Imaging the HIV Reservoir

This study aims to develop a method to accurately image the size and location of HIV persistence in HIV-infected individuals. The project aims to combine the broadly neutralizing anti-HIV antibody 3BNC117 with a Copper-64 radio isotope for use in a clinical trial.
The clinical trial has three different stages. The first stage is to recruit two HIV uninfected individuals and determine the safety of 3 mg/kg of 3BNC117 combined with Copper-64 and MRI/PET scanning at 1, 24 and 48 hours post infusion. The second stage is to examine the distribution on MRI/PET of the 3BNC117-Copper-64 combination in four HIV-infected individuals with viremia who are not receiving antiretroviral therapy. The final stage is to perform the same intervention in aviremic people with HIV receiving antiretroviral therapy.

  iconpaperstack View Older Articles   Back to Top   www.natap.org